Victoza in Cyprus, online

Hoe werkt Victoza?

Copies one gut hormone. Liraglutide is a copy of a natural gut hormone called GLP-1, which the body releases after eating. The EU product information describes it as an acylated human GLP-1 analogue with 97% amino acid sequence homology to the human hormone, and it binds to and activates the GLP-1 receptor.

Raises fullness, lowers hunger. GLP-1 receptors also sit in brain regions that regulate appetite. The product information reports that liraglutide increases feelings of fullness and satiety while lowering hunger and prospective food consumption, so people eat less. It does not increase energy expenditure compared with placebo.

Short-acting, so taken daily. Liraglutide has an elimination half-life of roughly 13 hours, which is why it is injected once every day rather than once a week like semaglutide or tirzepatide. It also raises insulin and lowers glucagon in a glucose-dependent way, and weight is lost mainly as fat mass.

Hoe gebruik je Victoza?

Inject once every day. Liraglutide is injected once daily, at any time of day, with or without food. Unlike weekly injections it needs a dose every 24 hours, so it is easiest to pick a convenient time and keep to it.

Start low and build up. Treatment starts at 0.6 mg once daily and rises by 0.6 mg at intervals of at least a week, reaching the 3.0 mg maintenance dose in week 5. The slow climb is there to improve stomach and bowel tolerance.

Tummy, thigh or upper arm. The injection goes under the skin of the abdomen, the thigh or the upper arm. It must never be given into a vein or a muscle. Rotate the site each day to reduce the risk of amyloid deposits building up under the skin.

Check the pen before use. Look at the liquid before you inject. It should be clear and colourless, or almost colourless. With a new pen, do the flow check described in the instructions so you can see a drop appear at the needle tip before setting your dose.

Missed dose: the 12 hour rule. If you remember within 12 hours of your usual time, take the dose as soon as you can. If there is less than 12 hours until the next one, skip it and carry on as normal. Never take an extra dose.

Store pens in the fridge. Unused pens are kept in a refrigerator between 2 and 8 degrees Celsius, away from the freezer compartment, and must not be frozen. A pen in use can be stored below 30 degrees Celsius or refrigerated, and is discarded one month after first use.

Drink enough fluid. Nausea, vomiting and diarrhoea are common at the start and can leave you short of fluid. Dehydration has been linked to kidney impairment and acute kidney failure on GLP-1 medicines, so drink plenty and tell your doctor if you cannot keep fluids down.

Keep the diet and activity going. Liraglutide is licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for them. Every trial result quoted on this page comes from people doing both alongside the daily injection.

Veelvoorkomende bijwerkingen

Stop and get urgent medical help if (seek medical help immediately): Severe and lasting pain in the stomach area that may reach through to your back, which can signal pancreatitis, Severe pain high in the tummy, usually worst on the right side under the ribs, which can signal gallstones or an inflamed gall bladder, Breathing problems, or swelling of the face, lips, tongue or throat, which can signal a severe allergic reaction, Vomiting or diarrhoea so severe or so lasting that you cannot keep fluids down, because dehydration can lead to kidney failure, Cold sweat, pale skin, shakiness, headache and confusion, if you also take insulin or a sulfonylurea for diabetes, A racing or pounding heartbeat while you are resting, which the prescriber needs to review, Severe stomach pain with bloating and no bowel movement, which can signal a blocked bowel

Very common (very common (≥1/10)): Feeling sick (nausea), most often while the dose is being increased, Being sick (vomiting), Diarrhoea, Constipation, Headache

Common (common (≥1/100 to <1/10)): Low blood sugar symptoms, self-reported and not confirmed by a blood glucose reading, in people without type 2 diabetes, Trouble sleeping, mainly during the first three months, Dizziness, A change in the sense of taste, Dry mouth, Indigestion, gastritis or acid reflux, Pain in the upper part of the tummy, Wind, burping or a bloated tummy, Gallstones, Rash, Injection site reactions, Weakness or tiredness, Raised lipase or amylase on blood tests

Uncommon (uncommon (≥1/1,000 to <1/100)): Dehydration, A faster heart rate (tachycardia), Pancreatitis, which is inflammation of the pancreas, Delayed stomach emptying, Inflammation of the gall bladder (cholecystitis), Nettle rash (urticaria), Generally feeling unwell

Rare (rare (≥1/10,000 to <1/1,000)): Anaphylactic reaction, a sudden and severe whole-body allergic reaction, Acute kidney failure, Kidney impairment

Frequency not known (frequency not known (cannot be estimated from the available data)): Intestinal obstruction, a blockage of the bowel, reported after the medicine went on the market, Cutaneous amyloidosis, a lumpy deposit that can build up under the skin at the injection site

Gebruik Victoza niet als

• You have ever had an allergic reaction to liraglutide or to any other ingredient in the pen. This is the only absolute contraindication in the EU product information.
• You are pregnant, or you want to become pregnant. Liraglutide should not be used in pregnancy, and treatment is discontinued if pregnancy occurs.
• You are breastfeeding. It is not known whether liraglutide passes into human milk, so it should not be used while breastfeeding.
• You or a close relative have had medullary thyroid carcinoma, or you have multiple endocrine neoplasia syndrome type 2. US labelling makes this an outright contraindication; EU labelling advises caution in anyone with thyroid disease.
• You have had pancreatitis. If pancreatitis is suspected liraglutide is stopped, and if it is confirmed it is not restarted.
• You have gallstones or gall bladder disease. Weight-management trials found more gallstones and gall bladder inflammation on liraglutide than on placebo.
• You have severe kidney impairment, including end-stage kidney disease, or severe liver impairment. Liraglutide is not recommended in these groups.
• You have inflammatory bowel disease or diabetic gastroparesis. Experience is limited and the medicine is not recommended, because it causes stomach and bowel effects.
• You already take another GLP-1 receptor agonist, or you would be using it as a replacement for insulin. Neither is allowed.
• You have New York Heart Association class IV heart failure, or you are 75 years or older. There is no clinical experience in these groups, so use is not recommended.

Geneesmiddelen en stoffen die een wisselwerking geven

• Insulin and sulfonylureas (for example gliclazide): Combined use in type 2 diabetes raises the risk of low blood sugar, sometimes severe. The prescriber may lower the insulin or sulfonylurea dose and asks for blood glucose self-monitoring.
• Other GLP-1 receptor agonists: Two medicines acting on the same receptor add side effects without an established extra benefit. Liraglutide for weight management must not be combined with another GLP-1 receptor agonist.
• Warfarin and other coumarin blood thinners: No interaction study was done, and a clinically relevant effect on warfarin cannot be excluded. The prescriber arranges more frequent INR checks when liraglutide is started.
• Oral medicines in general: Liraglutide slightly delays stomach emptying, which can slow how fast a tablet is absorbed. Interaction studies showed no clinically relevant delay, so no dose change is required.
• Paracetamol: Peak paracetamol level fell by 31% and was reached up to 15 minutes later; total exposure was unchanged. No dose adjustment is needed for paracetamol taken alongside liraglutide.
• Combined oral contraceptives: Peak ethinylestradiol and levonorgestrel levels fell by 12% and 13%, with no relevant change in total exposure. The contraceptive effect is expected to be unaffected, so no change is required.
• Atorvastatin, digoxin and lisinopril: Peak levels fell by 38%, 31% and 27% respectively, with only small changes in total exposure. No dose adjustment of any of these three is required based on those results.
• General anaesthesia or deep sedation: Delayed stomach emptying can leave food in the stomach, and pulmonary aspiration has been reported. Tell the anaesthetic team you take liraglutide before any procedure needing anaesthesia or sedation.

Bronnen

1. Saxenda (liraglutide): European public assessment report, medicine overview European Medicines Agency, 2015
2. Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics European Medicines Agency, 2026
3. Saxenda 6 mg/mL solution for injection in pre-filled pen: Summary of Product Characteristics electronic medicines compendium (emc), 2026
4. Saxenda 6 mg/mL solution for injection in pre-filled pen: Patient Information Leaflet electronic medicines compendium (emc), 2026
5. Liraglutide (Saxenda, Diavic, Zegluxen): NHS medicines A to Z NHS, 2026
6. SCALE Obesity and Prediabetes: a randomized, controlled trial of 3.0 mg of liraglutide in weight management New England Journal of Medicine, 2015
7. SCALE Maintenance: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss International Journal of Obesity, 2013
8. Victoza (liraglutide): European public assessment report, medicine overview European Medicines Agency, 2009
9. Saxenda (liraglutide) injection: US prescribing information, boxed warning and contraindications DailyMed, US National Library of Medicine, 2026
10. CIMA: Saxenda presentations, marketing and prescription status in Spain AEMPS (Spanish Agency of Medicines and Medical Devices), 2026
11. Sozialgesetzbuch V § 34: medicines excluded from statutory health insurance, including those for weight regulation Bundesministerium der Justiz (gesetze-im-internet.de), 2026
12. Liraglutide: preparaattekst and vergoeding conditions in the Netherlands Farmacotherapeutisch Kompas, Zorginstituut Nederland, 2026
13. Liraglutide (Saxenda): health technology assessment and HSE reimbursement decision National Centre for Pharmacoeconomics (Ireland), 2023
14. Rejestr Produktow Leczniczych: Saxenda registration record in Poland Centrum e-Zdrowia (Poland), 2026
15. INFOMED: base de dados de medicamentos de uso humano INFARMED (Portugal), 2026
16. STEP 1: Once-weekly semaglutide in adults with overweight or obesity New England Journal of Medicine, 2021
17. SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity New England Journal of Medicine, 2022
18. XENDOS: XENical in the prevention of Diabetes in Obese Subjects, a 4-year randomised study Diabetes Care, 2004
19. Wegovy (semaglutide) solution for injection: Summary of Product Characteristics electronic medicines compendium (emc), 2026
20. Xenical 120 mg hard capsules: Summary of Product Characteristics electronic medicines compendium (emc), 2026

Ook beschikbaar in

• Sevilla
• Málaga
• Córdoba
• Granada
• Jerez de la Frontera
• Almería
• Huelva
• Cádiz
• Jaén
• Marbella
• Zaragoza
• Huesca
• Teruel
• Oviedo
• Gijón
• Avilés
• Palma de Mallorca
• Ibiza
• Mahón
• Las Palmas de Gran Canaria
• Santa Cruz de Tenerife
• San Cristóbal de La Laguna
• Telde
• Arona
• Santander
• Toledo
• Valladolid
• Barcelona
• Valencia
• Alicante
• Mérida
• Vigo
• Santiago de Compostela
• Logroño
• Madrid
• Murcia
• Pamplona
• Bilbao
• Vitoria-Gasteiz
• San Sebastián
• Berlijn
• Hamburg
• München
• Keulen
• Frankfurt
• Stuttgart
• Düsseldorf
• Leipzig
• Dortmund
• Essen
• Parijs
• Marseille
• Lyon
• Toulouse
• Nice
• Nantes
• Montpellier
• Straatsburg
• Bordeaux
• Lille
• Rome
• Milaan
• Napels
• Turijn
• Palermo
• Genua
• Bologna
• Florence
• Bari
• Catania
• Warschau
• Krakau
• Łódź
• Wrocław
• Poznań
• Danzig
• Szczecin
• Bydgoszcz
• Amsterdam
• Rotterdam
• Den Haag
• Utrecht
• Eindhoven
• Groningen
• Tilburg
• Almere
• Brussel
• Antwerpen
• Gent
• Charleroi
• Luik
• Brugge
• Namur
• Lissabon
• Porto
• Vila Nova de Gaia
• Amadora
• Braga
• Coimbra
• Boekarest
• Cluj-Napoca
• Iași
• Timișoara
• Constanța
• Craiova
• Athene
• Thessaloniki
• Patras
• Piraeus
• Praag
• Brno
• Ostrava
• Pilsen
• Budapest
• Debrecen
• Szeged
• Miskolc
• Wenen
• Graz
• Linz
• Salzburg
• Stockholm
• Göteborg
• Malmö
• Uppsala
• Västerås
• Helsinki
• Espoo
• Tampere
• Vantaa
• Kopenhagen
• Aarhus
• Odense
• Aalborg
• Dublin
• Cork
• Limerick
• Galway
• Sofia
• Plovdiv
• Varna
• Burgas
• Bratislava
• Košice
• Prešov
• Žilina
• Zagreb
• Split
• Rijeka
• Osijek
• Vilnius
• Kaunas
• Klaipėda
• Šiauliai
• Panevėžys
• Ljubljana
• Maribor
• Celje
• Riga
• Daugavpils
• Liepāja
• Jelgava
• Tallinn
• Tartu
• Narva
• Nicosia
• Limassol
• Larnaca
• Paphos
• Luxemburg
• Esch-sur-Alzette
• Valletta
• Birkirkara
• Qormi
• Mosta
• Spanje
• Frankrijk
• Duitsland
• Italië
• Portugal
• Nederland
• België
• Ierland
• Polen
• Tsjechië
• Slowakije
• Hongarije
• Roemenië
• Bulgarije
• Griekenland
• Kroatië
• Slovenië
• Oostenrijk
• Denemarken
• Zweden
• Finland
• Estland
• Letland
• Litouwen
• Luxemburg
• Malta